Continuous IV monitoring system developer ivWatch announced that it appointed Jaclyn Lautz as its new chief operating officer.
Lautz assumes the newly created position at the company, having previously led its research and development division. Her new role will include manufacturing, human resources and operations as well in an effort to drive efficiency and scalability of projects, according to a news release.
In the position, Lautz will report to ivWatch president & CEO Gary Warren. Lautz has been with the company since 2018, having previously held the role of advisory manager in the pharmaceutical and life sciences operations at PricewaterhouseCoopers.
“I am extremely proud to appoint Jaclyn to [COO],” Warren said in the release. “As a proven and trusted leader in the organization, Jaclyn has played an instrumental role in our evolution of products and growth of our company. Jaclyn’s expertise will help accelerate our innovation agenda, drive productivity and further advance ivWatch as one integrated organization.”
Newport News, Va.-based ivWatch develops the FDA-cleared SmartTouch disposable sensor, which is indicated for the early detection of peripheral IV infiltration and extravasation events. When paired with the ivWatch patient monitor, the sensor helps to alert clinicians of infiltration and extravasation events often hours before they are detectable by visual or tactile examination.